Cardiac Amyloidosis in Older Adults: How Kidney Function and Other Conditions Shape Care

The clue was a pair of wrist splints. A retired schoolteacher in her late seventies had worn them for carpal tunnel for the better part of a decade, then had her right hand operated on, then her left. Nobody connected the wrists to the stairs, which had quietly become a two-stop climb. When her ankles started swelling and her kidney numbers drifted, three different specialists each saw one piece of the picture.

That fragmentation is the ordinary story of cardiac amyloidosis in older adults. The disease rarely announces itself. It borrows the symptoms of common conditions, heart failure with a normal pumping fraction, aortic valve narrowing, chronic kidney disease, and hides behind them for years.

This explainer follows the questions patients and families actually ask once the word amyloid is finally spoken: what is happening inside the heart, why the kidneys keep coming up in every conversation, and how age, frailty and other illnesses change what a care team can safely offer.

What is cardiac amyloidosis in older adults, and what actually happens in the heart?

Amyloid is not a single substance. It is what happens when a normally soluble protein loses its shape, sticks to copies of itself and settles in tissue as insoluble fibrils. In cardiac amyloidosis those fibrils lodge between heart muscle cells. The wall thickens, but not with useful muscle; it thickens with inert protein that resists stretching.

Think of a leather glove left out in the rain and dried on a radiator. It still looks like a glove. It simply no longer flexes. A heart in that state can often squeeze acceptably, which is why the standard measure of pumping strength, the ejection fraction, may read as normal. The trouble is filling. Blood backs up behind a chamber that will not relax, pressure rises in the lungs and the veins, and the person feels breathless and swollen even though a routine echocardiogram may be described as reassuring.

In older adults two proteins account for almost all cases. Transthyretin, abbreviated TTR, is a transport protein made by the liver; when it misfolds, the condition is called ATTR amyloidosis. The wild-type form, meaning no inherited mutation is present, is strongly age-related and predominantly affects men over 70, according to the American Heart Association scientific statement on cardiac amyloidosis. The hereditary form, caused by a gene variant, can appear earlier and is more common in some populations, including people of West African ancestry.

The second protein is an immunoglobulin light chain, a fragment of antibody produced by an abnormal clone of plasma cells in the bone marrow. This is AL amyloidosis. It behaves more like a blood disorder that happens to damage the heart, and it moves faster, which is why distinguishing the two is the first job of any diagnostic workup.

When to suspect amyloidosis: the clues that arrive years before breathlessness

Clinicians increasingly talk about “red flags” for amyloid, not as a self-diagnosis checklist but as a pattern that should make a doctor order the right test rather than the usual one. The pattern is worth understanding because many of the clues sit outside the heart.

Carpal tunnel syndrome on both sides is the best known. The same TTR protein that thickens the heart also collects in the tendon sheath at the wrist, and the AHA statement notes that this can precede cardiac symptoms by five to ten years. A spontaneous rupture of the biceps tendon, lumbar spinal stenosis and unexplained numbness or tingling in the feet belong to the same family of tissue deposits.

Inside the cardiology clinic, the clue is a mismatch. The heart wall looks thick on ultrasound, which would usually push the electrical tracing on an ECG toward tall, exaggerated complexes; in amyloid the voltages are often oddly small. Blood pressure that used to need two or three medicines suddenly needs none, or falls when the person stands, because the autonomic nerves that regulate it are also infiltrated. Heart failure that does not tolerate the standard drug classes, with dizziness or kidney strain at doses others manage easily, is another prompt.

Prevalence studies have sharpened this suspicion. In a screening study of people aged 60 and over admitted with heart failure, a preserved ejection fraction and a thickened left ventricular wall, wild-type ATTR was identified in roughly 13 percent using a bone-tracer scan, published in the European Heart Journal and indexed on PubMed. That is not a rare disease hiding in that particular group; it is one patient in eight.

None of these features proves anything on its own. Together they justify a targeted workup, and that is the point at which a conversation with a doctor becomes worthwhile.

Why kidney function matters so much in cardiac amyloidosis in older adults

Ask any amyloid cardiologist which number they check before every decision and most will name the estimated glomerular filtration rate, or eGFR, the routine blood-test estimate of how well the kidneys are filtering. It shapes care in at least four directions at once.

First, the kidneys may themselves be a target. In AL amyloidosis, light-chain deposits in the kidney’s filtering units are common, and the leak of protein into the urine is often the first laboratory abnormality anyone notices, as the NHS overview of amyloidosis describes. Wild-type ATTR spares the kidney more often, but decades of age-related decline, diabetes and high blood pressure mean many older patients arrive with reduced function anyway.

Second, the kidneys determine how safely fluid can be removed. A stiff heart depends on a narrow band of filling pressure: too much fluid and the lungs congest, too little and output collapses. Diuretics, the water tablets that make this adjustment, work through the kidney, and a kidney that is already struggling responds unpredictably.

Third, kidney function decides which tests are safe. Gadolinium contrast for cardiac MRI and iodinated contrast for CT or angiography are both handled by the kidney, and teams weigh their use carefully when eGFR is low. The technetium bone-tracer scan that has transformed ATTR diagnosis, described in the next section, has the practical advantage of needing no contrast at all.

Fourth, kidney function influences eligibility for disease-modifying treatment. Several of the newer classes were studied in people with eGFR above a threshold, and clinicians extrapolate cautiously below it. A prescribing team will always look at kidney numbers alongside the heart before recommending, deferring or adjusting any option. That judgment sits with them, not with a general article.

How the heart and kidneys pull in opposite directions when fluid builds up

Physicians call it the cardiorenal tightrope, and few conditions illustrate it as starkly as amyloid. Here is the mechanism in plain terms.

A healthy heart accommodates extra fluid by stretching a little and pumping harder. An amyloid heart cannot stretch. When fluid accumulates, pressure rises steeply inside the chambers and backs up into the veins, including the veins draining the kidneys. Congested kidneys filter poorly, so they hold onto salt and water, which raises pressure further. A loop forms.

Remove too much fluid, however, and the opposite problem appears. Because the stiff ventricle can only accept a small volume, a modest drop in blood volume translates into a sharp fall in what the heart can push forward. Blood pressure sags, the person feels faint on standing, and the kidneys, now underfilled rather than congested, again report rising creatinine. The same lab result, a worse kidney number, can mean either too much fluid or too little, and telling the two apart requires examination, weight trends and sometimes ultrasound rather than bloodwork alone.

This is why care teams often ask people with cardiac amyloidosis to weigh themselves each morning and keep a simple log. A steady drift upward over several days usually signals accumulating fluid; a rapid fall with lightheadedness may signal the reverse. The numbers help the clinician adjust treatment by phone before a hospital admission becomes necessary.

The Cleveland Clinic patient overview of cardiac amyloidosis makes a related point: several drug classes that are cornerstones of ordinary heart failure care, including beta blockers and certain blood pressure medicines, are frequently poorly tolerated in amyloid because they lower heart rate or pressure in a heart that depends on both. Any change to these medicines belongs to the prescribing clinician, who can weigh the trade-offs person by person.

ATTR cardiomyopathy diagnosis: scans, blood tests and when a biopsy is still needed

A generation ago, confirming cardiac amyloidosis meant a heart biopsy. Today, for the transthyretin type, it often does not, and understanding the modern pathway helps families follow what is being ordered and why.

The pathway begins with two blood tests and one urine test designed to answer a single question: is there an abnormal light chain in circulation? These are the serum free light chain assay and immunofixation of blood and urine. If all three are clean, AL amyloidosis is very unlikely.

The next step is a nuclear medicine scan using a technetium-labeled bone tracer, most often written as PYP or DPD depending on the country. For reasons still not fully understood, TTR deposits soak up this tracer avidly while AL deposits mostly do not. When the scan shows strong uptake in the heart and the light-chain tests are negative, guideline bodies including the AHA accept the combination as diagnostic of ATTR cardiomyopathy without a tissue sample. A cardiac MRI, when kidney function allows contrast, adds characteristic patterns of scarring and tissue mapping that support the picture.

Genetic testing follows any ATTR diagnosis, because the hereditary and wild-type forms carry different implications for relatives and for treatment choices. A simple blood test identifies whether a TTR gene variant is present.

Biopsy remains necessary in specific situations: when light-chain tests are abnormal, because AL must be typed at the tissue level; when the scan is equivocal; or when two processes may be present together. Older adults commonly have a benign excess of a single antibody protein, called MGUS, that can muddy the light-chain results without meaning AL is present, and this is one of the more frequent reasons a team will still request tissue. The sample may come from fat under the skin, the bone marrow or the heart itself, and the team will explain which and why.

AL versus ATTR: why the type changes everything, including how the kidneys are treated

Two people can sit in the same waiting room with the same thickened heart and the same swollen ankles and face entirely different diseases. The table summarizes the distinctions that matter most to older adults, drawn from the Mayo Clinic, NHS and AHA sources listed at the end.

Feature	AL (light chain)	ATTR wild-type	ATTR hereditary
Source of protein	Abnormal plasma cells in bone marrow	Normal liver protein misfolding with age	Inherited TTR gene variant
Typical age	Any adult age, often 60s and 70s	Mostly over 70, more often men	Varies by variant, may be earlier
Kidney involvement	Common, protein in urine frequent	Uncommon as a direct target	Possible with some variants
Nerve involvement	Possible	Carpal tunnel common	Often prominent
Pace	Faster, needs urgent evaluation	Slower, over years	Intermediate
Treatment principle	Suppress the plasma cell clone	Stabilize or reduce TTR production	Same as wild-type, plus family testing

The kidney column deserves a second look. In AL, protecting kidney function is a treatment goal in its own right, because the same light chains damaging the heart are damaging the filtering units, and hematologists track urine protein as closely as cardiologists track heart markers. In wild-type ATTR, kidney disease is usually a bystander condition of age rather than a target, but it still governs which medicines are safe and which scans are possible.

The pace difference is the reason clinicians move quickly when light-chain tests are abnormal. AL is managed primarily by hematology, using drug classes borrowed from myeloma care to switch off the clone, and the sooner that happens the less amyloid the heart has to absorb. ATTR allows more deliberation, but not indefinite delay.

Aortic stenosis, atrial fibrillation and the other heart conditions that travel with amyloid

Older hearts rarely have one problem. Amyloid frequently coexists with, and is mistaken for, several others, and each pairing changes the plan.

Aortic stenosis, a narrowing of the valve leaving the heart, is the most studied companion. Both conditions thicken the wall and both cause breathlessness on exertion, and it took systematic screening to reveal how often they overlap. The AHA scientific statement cites series in which around 16 percent of older adults undergoing valve replacement for severe aortic stenosis also had ATTR deposits. The finding matters because a valve procedure relieves the valve but not the amyloid; teams now often screen before valve intervention so expectations and follow-up are realistic.

Atrial fibrillation, an irregular and often rapid heart rhythm, is exceptionally common in cardiac amyloidosis because the upper chambers are infiltrated and stretched. Two consequences follow. Clots form readily in the sluggish atria, so anticoagulation is usually considered regardless of the risk scores used in ordinary practice, though kidney function and bleeding risk shape which class is chosen. And the standard rate-slowing medicines can be poorly tolerated, since the stiff heart relies on a brisker heart rate to maintain output.

Conduction disease, meaning slowed electrical signaling through the heart, is another frequent finding and a common reason for pacemaker discussion. Coronary artery disease may coexist simply by virtue of age, and small-vessel amyloid deposits can cause chest discomfort with clean large arteries on angiography.

Finally, the low or falling blood pressure seen in many amyloid patients often leads to the gradual withdrawal of antihypertensive medicines that were once essential. That decision, like every medicine decision in this condition, belongs to the prescribing team, who can see the whole picture rather than one reading.

Frailty, falls and why a comprehensive geriatric assessment changes the plan

Two eighty-year-olds with identical scans can have very different realities: one still gardening and driving, the other needing help to dress. Cardiology has borrowed a tool from geriatric medicine to capture that difference, and it increasingly steers amyloid care.

Frailty describes a reduced reserve across several body systems, so that a minor stress, a chest infection or a change in medicine, produces a disproportionate setback. It is measured rather than guessed, using simple tests such as walking speed over a short distance, grip strength, unintentional weight loss and self-reported exhaustion. A comprehensive geriatric assessment goes further, reviewing cognition, mood, nutrition, continence, mobility, social support and the full medicine list.

Why does this matter for amyloid specifically? Because the condition attacks several of the systems that keep older adults upright. Autonomic nerve involvement causes blood pressure to drop on standing, a leading cause of falls. Peripheral nerve involvement dulls sensation in the feet. Diuretics add urgency to nighttime bathroom trips. Add the ordinary dizziness of an underfilled stiff heart and the risk of a fracture becomes a central concern, not a footnote.

A geriatric review also tackles polypharmacy, the accumulation of medicines that made sense individually but interact poorly together. Older adults with amyloid commonly arrive on treatments for blood pressure, prostate symptoms, sleep and pain that all lower pressure or cloud alertness. Streamlining that list, always through the prescribing clinicians, can improve daily function more than any single new therapy.

Frailty does not disqualify anyone from treatment. It reframes the goal. For some, the priority becomes fewer hospital admissions and steadier days at home; for others, a more intensive disease-modifying course remains appropriate. The assessment simply ensures the plan fits the person rather than the scan.

What treatment involves, and how kidney and other conditions shape it

Treatment for cardiac amyloidosis runs on two parallel tracks: managing the consequences in the heart, and slowing or stopping the supply of misfolded protein. Both tracks are adjusted around the other conditions an older adult carries.

The first track is familiar heart failure care, adapted. Loop diuretics remain the backbone for fluid control, dosed and re-dosed against daily weights and kidney numbers by the prescribing clinician. A mineralocorticoid receptor antagonist, a second diuretic class that also blocks a salt-retaining hormone, is sometimes added, but it can raise potassium, and reduced kidney function makes that more likely, so blood tests are frequent. Anticoagulation for atrial fibrillation is chosen with kidney clearance in mind. Pacemakers address slow rhythms.

The second track depends on type. For AL, hematologists use combinations of drug classes that target plasma cells, including proteasome inhibitors and monoclonal antibodies, with the aim of driving light-chain production down quickly; the Mayo Clinic overview describes this approach in general terms. Kidney involvement influences which agents and schedules are chosen, and the heart’s fragility influences how aggressively.

For ATTR, the options work on the protein itself. TTR stabilizers, of which tafamidis is the generic example, bind the protein and keep it from splitting into the fragments that form fibrils; the AHA statement describes a randomized trial in which this class was associated with fewer deaths and cardiovascular hospitalizations over 30 months compared with placebo. Gene-silencing therapies, given by injection, reduce the liver’s production of TTR and were developed first for the nerve-predominant hereditary form. Trial populations for these classes were defined partly by kidney function, and a treating team weighs that carefully.

Nothing here is a recommendation. The mechanisms are described so that the conversation with a prescribing clinician makes sense; the choices, including whether to start, continue or change any medicine, remain with them.

Who is usually offered disease-modifying treatment, and who is usually asked to wait

Patients often assume that a confirmed diagnosis means immediate treatment. In practice, teams sort people into broad groups, and the reasoning is worth knowing in advance so that a pause does not feel like abandonment.

Those usually offered ATTR-directed therapy promptly have a confirmed diagnosis by scan or biopsy, symptoms of heart failure that are present but not end-stage, and a functional status that suggests they will live long enough to benefit from a slow-acting treatment. Because stabilizers and silencers prevent new deposits rather than dissolving old ones, the AHA statement and most clinicians frame their value in terms of years of slower decline, which favors earlier rather than later starts.

Those usually asked to wait, or to be reassessed first, include people whose diagnosis is not yet secure, for instance a positive bone scan alongside abnormal light chains, where AL must be excluded before ATTR treatment is considered. People whose kidney function falls below the range studied may be asked to wait while the team reviews the evidence for their situation. Those in the middle of another acute illness are often stabilized first.

A third group is the most delicate: people with very advanced heart failure or profound frailty, for whom a slow-acting therapy may offer little and a heavy monitoring schedule may cost more than it gives. Here teams talk openly about goals, and some choose comfort-focused care with excellent symptom control instead.

For AL, the calculus is different. Because the disease progresses fast, treatment is rarely deferred once typing is confirmed; the question is which combination the heart and kidneys can tolerate, not whether to begin. Every one of these decisions belongs to the treating team, informed by the person’s own priorities.

What the first weeks and months after diagnosis usually look like

The period after diagnosis is often busier than the years of vague symptoms that preceded it. Knowing the typical shape of it helps families plan.

The first two to four weeks are usually about completing the picture. Genetic testing results for TTR variants typically return within a few weeks. If light-chain tests were abnormal, a hematology referral and possibly a bone marrow test happen quickly, because AL timelines are short. Baseline blood markers of heart strain, kidney function and, where relevant, urine protein are recorded so that later changes can be measured against them.

Medicines are often adjusted in this window, and it can feel counterintuitive. Blood pressure treatments may be stepped down while diuretics are fine-tuned; a beta blocker that has been taken for years may be reconsidered. Expect frequent blood tests during any change, since the kidney response guides the next step.

By the second or third month, most people have a settled plan: a named cardiologist, sometimes a hematologist, and a schedule of follow-up. Disease-modifying treatment for ATTR, if chosen, is typically underway; the AHA statement notes that measurable differences in outcomes emerged over months to years in trials, not weeks, so an absence of dramatic change early is expected and not a sign of failure.

Routine follow-up thereafter often settles into visits every three to six months with scans repeated annually, though the interval varies with stability and the team’s judgment. Between visits, the daily weight log and a low threshold for calling about breathlessness, swelling or dizziness do most of the work of keeping people out of hospital.

Family members of anyone with hereditary ATTR are usually offered genetic counseling in this period, a conversation that carries its own timeline and emotions.

Living day to day: activity, salt, fluids and the questions about exercise

People ask whether exercise helps amyloidosis, and the honest answer is that the evidence is thin and the answer is individual. No large trial has tested structured exercise in cardiac amyloidosis specifically. What exists comes from heart failure more broadly, where supervised, moderate activity improves function and mood, and from clinical experience that people who keep moving fall less and recover faster from setbacks.

The amyloid-specific caveat is blood pressure. Because the autonomic nerves may be involved, exertion followed by an abrupt stop can cause a steep pressure drop and fainting. Teams therefore tend to favor steady, moderate activity with a gradual cool-down, and to warn against sudden heavy lifting or straining. Many refer suitable patients to cardiac rehabilitation programs, where the intensity is supervised and the heart rate response is watched. The right level is something to agree with the care team rather than guess.

Salt and fluid advice mirrors heart failure care but requires more precision. A stiff heart is intolerant of both congestion and dehydration, so blanket instructions to drink less or more can misfire. Most teams set a personal fluid range and a modest salt limit, then adjust them against the weight log. Hot weather, vomiting or diarrhea can tip the balance within a day and warrant a phone call.

Nutrition matters in a quieter way. Amyloid can infiltrate the gut, causing early fullness, unintended weight loss and altered bowel habit. Smaller, more frequent meals and a review with a dietitian help preserve muscle, which in turn protects against frailty.

Vaccination against influenza, pneumococcal disease and other respiratory infections is generally encouraged in heart failure, because infections are among the commonest triggers of decompensation in this group, as the Cleveland Clinic overview notes. Timing and suitability are for the clinician to confirm.

What people often get wrong about cardiac amyloidosis

Myths gather around rare diagnoses, and several of them cause real harm by delaying the right test or the right conversation.

“A normal ejection fraction means the heart is fine.” This single misunderstanding accounts for many missed years. Ejection fraction measures squeeze, not stiffness. A heart can empty a normal fraction of a chamber that barely filled in the first place. Breathlessness with a normal reading is a reason to look harder, not to stop.

“Amyloidosis is always a cancer.” AL amyloidosis arises from a plasma cell clone and is managed by hematologists using cancer-derived drug classes, but many AL clones are small and do not meet criteria for myeloma. ATTR has nothing to do with cancer at all; it is a protein-folding disorder of aging or inheritance.

“It only affects men.” Wild-type ATTR is more common in men, but women are diagnosed, often later, partly because their hearts are smaller and the thickness thresholds used to trigger suspicion were set in men. Hereditary and AL forms affect both sexes.

“The carpal tunnel surgery fixed the problem.” Wrist surgery relieves the pressure on the nerve. It does nothing to the deposits elsewhere, and a history of bilateral carpal tunnel in an older adult remains a clue worth mentioning to a cardiologist years later.

“Kidney trouble means the diuretic must be stopped.” Sometimes it means the opposite. A rising creatinine can reflect congestion that more diuretic would relieve. Only the prescribing clinician, with an examination and weight trend, can tell which direction is right.

“Nothing can be done at this age.” The treatment landscape for ATTR has changed substantially, and symptom-focused care is highly effective regardless of age. Age is a factor in planning, not a reason to skip the assessment.

Questions to ask your care team

A first amyloid consultation delivers a lot of information in a short time. Bringing questions, and a second pair of ears, turns it into a dialogue. These are the ones experienced patients say they wish they had asked earlier.

• Which type of amyloidosis do I have, and how certain is that? Has AL been excluded by blood and urine testing, or is a biopsy still needed?
• Was genetic testing done for a TTR variant, and if so, what does the result mean for my children and siblings?
• What is my current kidney function, and how does it affect which medicines and scans you can safely use for me?
• Which of my existing medicines are you considering changing because of amyloid, and what should I watch for during the change?
• What is my target weight range, and at what change in weight, swelling or breathlessness should I call rather than wait for the next appointment?
• Am I a candidate for a disease-modifying treatment now? If not, what would need to change, and when will you reassess?
• Do I have atrial fibrillation or conduction disease, and is anticoagulation or a pacemaker part of the plan?
• Has anyone assessed my fall risk and my blood pressure on standing?
• Which specialists are involved in my care, and who coordinates between them?
• Is there a clinical trial that might be appropriate for my situation?

Notice how many of these questions circle back to the kidneys. That is deliberate. Kidney function is the hinge on which fluid management, drug choice, imaging and eligibility all turn, and a patient who understands their own eGFR trend is far better placed to follow the team’s reasoning.

Write the answers down. Amyloid care unfolds over years, and the notes from an early visit often make sense of a decision taken much later.

When to call your doctor

Most of cardiac amyloidosis is managed in clinic and by phone, but certain changes should not wait for a scheduled visit. The team will have given a direct line for this reason; use it.

Call the same day for breathlessness that is new, worse or now present when lying flat; for weight rising by more than a couple of pounds over two or three days or swelling climbing above the ankles; for lightheadedness on standing, a near-faint or a fall; for a new irregular, racing or unusually slow pulse; for markedly reduced urine output; or for vomiting or diarrhea lasting more than a day, since fluid loss can destabilize a stiff heart quickly. A change in bleeding or bruising while on an anticoagulant also warrants a call.

Seek emergency care immediately for fainting, chest pain or pressure that does not settle within minutes, severe breathlessness at rest, confusion or difficulty speaking, sudden weakness on one side of the body, or coughing up pink or frothy sputum. These can signal a dangerous rhythm, a stroke or acute lung congestion, all of which are treatable when reached quickly, as MedlinePlus and the Mayo Clinic overviews of cardiac amyloidosis describe.

Between those extremes lies a wide gray zone, and the guidance from experienced teams is consistent: call early and call often. An unnecessary phone call costs a few minutes. A delayed one can cost a hospital admission or worse. Families who live with amyloid learn to trust the weight log, the pattern of a normal day and their own sense that something is off, and to hand that information to the clinicians who can act on it.

Frequently asked questions

Can you live a normal life with AL amyloidosis?

Many people with AL amyloidosis return to a full daily routine once the plasma cell clone is controlled, but the outlook depends heavily on how much the heart and kidneys were affected before treatment began. Hematology-led therapy aims to switch off light-chain production quickly; heart and kidney recovery is slower and variable. Your treating team can describe what your own organ markers suggest.

What is the best hospital in the US for amyloidosis?

No single center can be called best, and rankings rarely reflect what matters for an individual. What helps is a team experienced in amyloid that includes cardiology, hematology, nephrology and, for older adults, geriatric input, with access to bone-tracer scanning, genetic testing and clinical trials. Ask your current cardiologist which specialist services they work with and how referrals are coordinated.

When to suspect amyloidosis in an older adult with heart failure?

Clinicians suspect amyloidosis when heart failure comes with a thickened heart wall but a normal ejection fraction, small ECG voltages, a history of bilateral carpal tunnel or spinal stenosis, blood pressure that has fallen without explanation, or poor tolerance of standard heart failure medicines. These clues prompt targeted testing rather than a diagnosis on their own, so raise them with a doctor.

Does exercise help amyloidosis?

The evidence is limited and comes mostly from general heart failure research, where supervised moderate activity improves function and mood. In cardiac amyloidosis, blood pressure can drop sharply after exertion because autonomic nerves are affected, so teams usually favor steady activity with a slow cool-down, often through cardiac rehabilitation. Agree the intensity with your care team rather than testing limits alone.

What are amyloid heart disease symptoms in elderly people that differ from ordinary heart failure?

The differences clinicians notice are outside the heart: numbness or tingling in the feet, bilateral carpal tunnel, lightheadedness on standing, early fullness after meals, and blood pressure that has fallen so that old medicines are no longer needed. The heart symptoms themselves, breathlessness and swelling, look like any heart failure, which is exactly why the condition is missed.

How does ATTR cardiomyopathy diagnosis work without a biopsy?

Doctors first exclude light-chain disease with a serum free light chain test and immunofixation of blood and urine. If those are negative and a technetium bone-tracer scan shows strong uptake in the heart, guideline bodies accept the combination as diagnostic of ATTR cardiomyopathy. Genetic testing then distinguishes hereditary from wild-type disease. A biopsy is still needed when light-chain tests are abnormal or the scan is unclear.

Why does my kidney function affect which amyloid treatments I can have?

Several disease-modifying therapies were studied mainly in people whose kidney function was above a set threshold, so evidence below it is thinner and prescribers proceed cautiously. Kidney function also governs diuretic response, potassium handling with certain heart failure drugs, anticoagulant choice and whether contrast scans are safe. Your team weighs all of these together, which is why eGFR comes up at nearly every visit.

Is cardiac amyloidosis hereditary?

Sometimes. Hereditary ATTR is caused by a variant in the TTR gene and can run in families, which is why genetic testing follows every ATTR diagnosis and relatives are offered counseling. Wild-type ATTR, the most common form in older adults, is not inherited; it results from age-related misfolding of a normal protein. AL amyloidosis is not passed on to children.

Why were my blood pressure medicines reduced after the amyloid diagnosis?

Amyloid can infiltrate the nerves that regulate blood pressure and stiffen the heart so that it depends on adequate pressure and heart rate to keep blood moving. Medicines that once controlled high blood pressure may now cause faintness or kidney strain. Adjusting them is a common and deliberate step, but it is always the prescribing clinician’s decision based on your readings and symptoms.

How often will I need follow-up scans and blood tests?

Patterns vary, but many teams see people every three to six months once stable, with blood tests for heart strain markers and kidney function at each visit and imaging roughly yearly. During medicine changes or after a hospital stay, testing is more frequent. Your team will set the interval based on your stability, your kidney trend and whether you are on a disease-modifying treatment.

References

• Amyloidosis (NHS)
• Cardiac amyloidosis (MedlinePlus Medical Encyclopedia)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.